Treatment of head and neck cancer with CHART and nimorazole: Phase II study

Radiotherapy and Oncology

Volumn 66, Issue 1, 2003, Pages 65-70

  Henk, J Michael ^a   Bishop, Kate ^a   Shepherd, Stephen F ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Accelerated radiotherapy; Head and neck cancer; Nimorazole

Indexed keywords

CARBAMAZEPINE; CYCLIZINE; DEXAMETHASONE; METOCLOPRAMIDE; NIMORAZOLE;

ARTICLE; BRAIN DISEASE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; VOMITING;

EID: 0037247313     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00284-0     Document Type: Article

References (18)

1. Cottrill C.P., Bishop K., Walton M.I., Henk J.M. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "CHART" regimen in head and neck cancer. Int J Radiat Oncol Biol Phys. 42:1998;807-810.
2. Dische S., Saunders M., Barrett A., Harvey A., Gibson D., Parmar M. A randomized multicenter trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 44:1997;123-136.
3. Eschwege F., Sancho-Garnier H., Chassagne D., et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinoma. Int J Radiat Oncol Biol Phys. 39:1997;275-281.
4. Henk J.M., A'Hern R.P. Overview of normal tissue effects in the head and neck of simultaneous radiotherapy and chemical agents. Br J Cancer. 74:(Suppl 28):1996;21.
5. Henk J.M. Does hyperbaric oxygen have a future in radiation therapy. Int J Radiat Oncol Biol Phys. 7:1981;1125-1128.
6. Horiot J.-C., Bontemps P., van den Bogaert W. Accelerated fractionation compared to conventional fractionation improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 44:1997;111-121.
7. Huilgol N.G., Chatterjee N., Mehta A.R. An overview of the initial experience with AK-2123 as a hypoxic-cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int J Radiat Oncol Biol Phys. 34:1996;1121-1124.
8. Kanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 51:2001;83-84.
9. Lee D.-J., Cosmatos D., Marcial V., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 32:1995;567-576.
10. Overgaard J., Hansen H.S., Grau C., et al. The DAHANCA 6 & 7 trial. A randomized multicentre study of 5 versus 6 fractions per week of conventional radiotherapy of squamous carcinoma of the head and neck. Radiother Oncol. 56:2000;S4.
11. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double blind phase III study of nimorazole as a hypoxic cell radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx cancer. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 46:1998;135-146.
12. Overgaard J., Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 6:1996;10-21.
13. Overgaard J., Overgaard M., Nielson O.S., Pederson K.A., Timothy A.R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 46:1982;904-911.
14. Saunders M.I., Dische S., Barrett A., Parmar M.K.B., Harvey A., Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer. 73:1996;1455-1462.
15. Saunders M.I., Dische S., Hong A., et al. Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region. Int J Radiat Oncol Biol Phys. 17:1989;1287-1293.
16. Skov K.A., MacPhail S. Low concentrations of nitroimidazoles: effective radiosensitizers at low dose. Int J Radiat Oncol Biol Phys. 29:1994;87-93.
17. Tobias J., Ball D. Synchronous chemoradiation of squamous carcinoma: this has become the gold standard - whatever the primary site. Br Med J. 322:2001;676-677.
18. Wylie J.P., Sen M., Swindell R., et al. Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome. Radiother Oncol. 53:1999;15-21.